210 related articles for article (PubMed ID: 36781850)
1. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
[TBL] [Abstract][Full Text] [Related]
2. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
Forgione MO; McClure BJ; Eadie LN; Yeung DT; White DL
Cancer Lett; 2020 Jan; 469():410-418. PubMed ID: 31705930
[TBL] [Abstract][Full Text] [Related]
3. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
[TBL] [Abstract][Full Text] [Related]
4. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract][Full Text] [Related]
5. Therapy-induced Deletion in 11q23 Leading to Fusion of
Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.
Bergmann AK; Castellano G; Alten J; Ammerpohl O; Kolarova J; Nordlund J; Martin-Subero JI; Schrappe M; Siebert R
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27786413
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Moskop A; Pommert L; Thakrar P; Talano J; Phelan R
Pediatr Blood Cancer; 2021 Jan; 68(1):e28739. PubMed ID: 33009894
[TBL] [Abstract][Full Text] [Related]
8. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
[TBL] [Abstract][Full Text] [Related]
9. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
[TBL] [Abstract][Full Text] [Related]
10. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
14. The role of constitutive activation of FMS-related tyrosine kinase-3 and
Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
[No Abstract] [Full Text] [Related]
15. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
[TBL] [Abstract][Full Text] [Related]
16. Quantification of NG2-positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia.
Zerkalenkova E; Mikhaylova E; Lebedeva S; Illarionova O; Baidun L; Kashpor S; Osipova E; Maschan M; Maschan A; Novichkova G; Olshanskaya Y; Popov A
Genes Chromosomes Cancer; 2021 Feb; 60(2):88-99. PubMed ID: 33135273
[TBL] [Abstract][Full Text] [Related]
17. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
Issa GC; Zarka J; Sasaki K; Qiao W; Pak D; Ning J; Short NJ; Haddad F; Tang Z; Patel KP; Cuglievan B; Daver N; DiNardo CD; Jabbour E; Kadia T; Borthakur G; Garcia-Manero G; Konopleva M; Andreeff M; Kantarjian HM; Ravandi F
Blood Cancer J; 2021 Sep; 11(9):162. PubMed ID: 34588432
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia.
Sharma R; Incoronato A; Zhang C; Jayanthan A; Shah R; Narendran A
J Pediatr Hematol Oncol; 2023 Aug; 45(6):e750-e756. PubMed ID: 37494611
[TBL] [Abstract][Full Text] [Related]
19. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
